Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-87801493
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
JNJ-87801493 is a novel, fully human, IgG1 bispecific monoclonal antibody under development for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. It is designed to bind both CD20 on B-cells and the CD28 receptor on T-cells, providing targeted costimulatory activation of T-cells in proximity to malignant B-cells. The drug leverages XmAb bispecific Fc technology and is administered subcutaneously. Its mechanism aims to enhance anti-tumor immune responses by engaging both tumor cells (via CD20) and activating T-cell costimulation (via CD28). JNJ-87801493 is currently in Phase 1 clinical trials as monotherapy and in combination with T-cell engagers for various subtypes of B-cell non-Hodgkin lymphoma[1][3][4][9].
- Other names
- CD20xCD28 bispecific antibodyCD-20xCD28 bispecific antibodyCD 20xCD28 bispecific antibody
02
Targets
CD20 (B-lymphocyte antigen CD20)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on JNJ-87801493.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-87801493.